May 17, 2010 - The world of genomics and medical imaging are joining forces in an effort to provide early detection diagnostics to patients with cardiovascular disease.
This market trend has prompted GE Healthymagination Fund, a new $250 million equity fund, to make its first investment in a cardiovascular genomic diagnostics company. The fund, part of GE's Healthymagination Fund, invested $5 million in CardioDx as part of a series D round that the fund is leading. CardioDx develops genomic tests to aid in the assessment and tailoring of care of individuals with cardiovascular diseases such as coronary artery disease (CAD), cardiac arrhythmias and heart failure.
CardioDx’s initial product, Corus CAD, is a noninvasive genomic test that uses data, such as gene expression levels and other patient characteristics, to assess the probability of a patient having obstructive CAD.
GE's cardiovascular imaging and monitoring business is making a strategic fit with CardioDx to expand capabilities in product research and development for the diagnosis and care of patients with suspected heart disease.
For more information: www.gehealthcare.com and
April 25, 2024 
